How does semaglutide work?
Semaglutide is a long-acting GLP-1 receptor agonist — it engages the GLP-1 receptor on pancreatic beta cells, gastric tissue, and central nervous system regions, mimicking the actions of native glucagon-like peptide 1 with a multi-day plasma half-life supporting once-weekly dosing.
What the research literature says
Semaglutide is a 31-amino-acid synthetic analogue of native GLP-1(7-37) with three engineering modifications: an aminoisobutyric acid substitution at position 8 (the canonical DPP-IV cleavage site) for protease resistance, a substitution at position 34, and a C18 fatty-acid sidechain attached via a spacer that mediates reversible non-covalent binding to serum albumin. The albumin-binding sidechain is the engineering feature that drives the ~7-day plasma half-life.
At the GLP-1 receptor, semaglutide produces the canonical incretin-hormone pharmacology: glucose-dependent insulin secretion from pancreatic beta cells (more insulin released when blood glucose is elevated, less when normal), glucagon suppression, slowed gastric emptying, and centrally-mediated effects on appetite and food intake. The integrated metabolic effect drives the glycemic-control and weight-reduction outcomes observed across the clinical-trial programs.
The published clinical-trial data is extensive. The Marso cardiovascular-outcomes trial established the cardiovascular-safety signal in type 2 diabetes (PMID 27633186). The SUSTAIN program covered the type 2 diabetes indication (SUSTAIN 1, PMID 28110911). The Blundell appetite and food-intake work characterised the centrally-mediated arm (PMID 28266779). The STEP and SELECT programs extended the framework into obesity and obesity-cardiovascular-outcomes contexts (PMID 33567185, PMID 37952131). The Gabery rodent work characterised the distributed neural pathways mediating weight loss (PMID 32213703).
Why this matters in research context
Semaglutide is the most extensively studied long-acting GLP-1 receptor agonist in the published clinical and preclinical literature. Research protocols using semaglutide can anchor experimental design to the well-characterised single-receptor pharmacology and the substantial dose-response and time-course dataset from the SUSTAIN, STEP, and SELECT programs. The compound serves as the comparison baseline for evaluating dual-receptor (tirzepatide) and triple-receptor incretin agonists.
Related compounds
- Semaglutide 10mg — the compound covered by this answer
- Tirzepatide 10mg — dual-receptor extension (adds GIP)
Related research questions
- What is the half-life of semaglutide?
- Is semaglutide FDA approved?
- How do semaglutide and tirzepatide differ?
References
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375(19):1834-1844. [PMID 27633186]
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol 2017;5(4):251-260. [PMID 28110911]
- Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 2017;19(9):1242-1251. [PMID 28266779]
- Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 2020;5(6):e133429. [PMID 32213703]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Semaglutide is sold strictly as a research-grade reagent for laboratory and bench research applications.